New candidate blood biomarkers potentially associated with white matter hyperintensities progression.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
12 07 2021
Historique:
received: 10 03 2021
accepted: 18 06 2021
entrez: 13 7 2021
pubmed: 14 7 2021
medline: 6 11 2021
Statut: epublish

Résumé

We aimed to discover blood biomarkers associated with longitudinal changes in white matter hyperintensities (WMH). This study was divided into a discovery phase and a replication phase. Subjects in both studies were patients with hypertension, aged 50-70, who underwent two magnetic resonance imaging (MRI) sessions and blood extractions over a 4-year follow-up period. In the discovery phase, we screened 1305 proteins in 12 subjects with WMH progression and in 12 matched control subjects. We found that 41 proteins were differentially expressed: 13 were upregulated and 28 were downregulated. We subsequently selected three biomarkers for replication in baseline and follow-up samples in 80 subjects with WMH progression and in 80 control subjects. The selected protein candidates for the replication were MMP9 (matrix metalloproteinase-9), which was higher in cases, MET (hepatocyte growth factor receptor) and ASAH2 (neutral ceramidase), which were both lower in cases of WMH progression. Baseline biomarker concentrations did not predict WMH progression. In contrast, patients with WMH progression presented a steeper decline in MET over time. Furthermore, cases showed higher MMP9 and lower ASAH2 levels than controls at the follow-up. These results indicate that MMP9, MET, and ASAH2 are potentially associated with the progression of WMH, and could therefore be interesting candidates to validate in future studies.

Identifiants

pubmed: 34253757
doi: 10.1038/s41598-021-93498-w
pii: 10.1038/s41598-021-93498-w
pmc: PMC8275657
doi:

Substances chimiques

Biomarkers 0
Proto-Oncogene Proteins c-met EC 2.7.10.1
Matrix Metalloproteinase 9 EC 3.4.24.35
ASAH2 protein, human EC 3.5.1.23
Neutral Ceramidase EC 3.5.1.23

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

14324

Informations de copyright

© 2021. The Author(s).

Références

Circulation. 2005 Aug 9;112(6):900-5
pubmed: 16061741
Neurology. 2008 Jul 8;71(2):108-13
pubmed: 18606964
J Am Geriatr Soc. 2020 Oct;68(10):2232-2239
pubmed: 32511756
Circulation. 2017 May 23;135(21):2028-2040
pubmed: 28280233
J Alzheimers Dis. 2018;64(4):1235-1246
pubmed: 30010121
Stroke. 2004 Jun;35(6):e159-62
pubmed: 15105518
Sci Rep. 2017 Oct 27;7(1):14248
pubmed: 29079756
Ann N Y Acad Sci. 2002 Nov;977:306-14
pubmed: 12480766
J Alzheimers Dis. 2015;45(4):985-1000
pubmed: 25649658
J Neurol Sci. 2020 Feb 15;409:116635
pubmed: 31869590
Neurobiol Aging. 2010 Mar;31(3):398-408
pubmed: 18547682
BMC Neurol. 2013 Oct 02;13:130
pubmed: 24083440
Neurology. 2014 Nov 11;83(20):1844-52
pubmed: 25320101
Acta Neurol Scand. 2003 Feb;107(2):81-6
pubmed: 12580855
Proteomics. 2020 Jun;20(12):e1900278
pubmed: 32386347
J Cereb Blood Flow Metab. 2016 Jan;36(1):26-39
pubmed: 25899293
Dement Geriatr Cogn Dis Extra. 2014 Oct 21;4(3):385-94
pubmed: 25493088
ScientificWorldJournal. 2010 Mar 16;10:457-61
pubmed: 20305987
AJR Am J Roentgenol. 1987 Aug;149(2):351-6
pubmed: 3496763
Cell Mol Life Sci. 2019 Aug;76(16):3117-3140
pubmed: 31165904
Adv Biol Regul. 2017 Jan;63:122-131
pubmed: 27771292
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Lancet Neurol. 2013 May;12(5):483-97
pubmed: 23602162
Nat Rev Neurol. 2015 Mar;11(3):157-65
pubmed: 25686760
J Cereb Blood Flow Metab. 2016 Jan;36(1):55-71
pubmed: 25899297
Genome Res. 2003 Nov;13(11):2498-504
pubmed: 14597658
Nat Protoc. 2019 Feb;14(2):482-517
pubmed: 30664679
Lancet Neurol. 2010 Jul;9(7):689-701
pubmed: 20610345
Stroke. 2010 Apr;41(4):600-6
pubmed: 20167919
Cerebrovasc Dis. 2016;42(1-2):66-72
pubmed: 27031692
Neurobiol Aging. 2012 Aug;33(8):1800-6
pubmed: 21601314
J Alzheimers Dis. 2011;27(3):665-76
pubmed: 21860087
Eur Neurol. 2014;72(3-4):234-40
pubmed: 25248031
Hypertension. 2019 Feb;73(2):342-349
pubmed: 30606062
Front Aging Neurosci. 2018 Jan 23;10:8
pubmed: 29410622
Hypertension. 2013 Nov;62(5):810-7
pubmed: 23980072
Circulation. 2018 Nov 27;138(22):2482-2485
pubmed: 30524136
Stroke. 2016 Nov;47(11):2689-2694
pubmed: 27729582
Stroke. 2008 Oct;39(10):2712-9
pubmed: 18635849
Neurology. 2004 May 11;62(9):1533-9
pubmed: 15136677
Mol Ther Nucleic Acids. 2014 Oct 07;3:e201
pubmed: 25291143
Bioinformatics. 2007 Dec 1;23(23):3251-3
pubmed: 17644558
Lancet Neurol. 2019 Jul;18(7):684-696
pubmed: 31097385
Neurology. 2012 Mar 6;78(10):720-7
pubmed: 22357713
Am J Hypertens. 2012 Oct;25(10):1088-94
pubmed: 22739806

Auteurs

Joan Jiménez-Balado (J)

Neurovascular Research Lab. Vall D'Hebron Research Institute, Universitat Autònoma de Barcelona, Edifici Mediterrània, Planta 1ª, Laboratori 123, Passeig Vall d'Hebron 119-129, 08035, Barcelona, CP, Spain.

Jesús Pizarro (J)

Neurovascular Research Lab. Vall D'Hebron Research Institute, Universitat Autònoma de Barcelona, Edifici Mediterrània, Planta 1ª, Laboratori 123, Passeig Vall d'Hebron 119-129, 08035, Barcelona, CP, Spain.

Iolanda Riba-Llena (I)

Neurovascular Research Lab. Vall D'Hebron Research Institute, Universitat Autònoma de Barcelona, Edifici Mediterrània, Planta 1ª, Laboratori 123, Passeig Vall d'Hebron 119-129, 08035, Barcelona, CP, Spain.

Anna Penalba (A)

Neurovascular Research Lab. Vall D'Hebron Research Institute, Universitat Autònoma de Barcelona, Edifici Mediterrània, Planta 1ª, Laboratori 123, Passeig Vall d'Hebron 119-129, 08035, Barcelona, CP, Spain.

Júlia Faura (J)

Neurovascular Research Lab. Vall D'Hebron Research Institute, Universitat Autònoma de Barcelona, Edifici Mediterrània, Planta 1ª, Laboratori 123, Passeig Vall d'Hebron 119-129, 08035, Barcelona, CP, Spain.

Elena Palà (E)

Neurovascular Research Lab. Vall D'Hebron Research Institute, Universitat Autònoma de Barcelona, Edifici Mediterrània, Planta 1ª, Laboratori 123, Passeig Vall d'Hebron 119-129, 08035, Barcelona, CP, Spain.

Joan Montaner (J)

Neurovascular Research Lab. Vall D'Hebron Research Institute, Universitat Autònoma de Barcelona, Edifici Mediterrània, Planta 1ª, Laboratori 123, Passeig Vall d'Hebron 119-129, 08035, Barcelona, CP, Spain.
Institute de Biomedicine of Seville, IBiS/Hospital Universitario Virgen del Rocío/CSIC/University of Seville & Department of Neurology, Hospital Universitario Virgen Macarena, Seville, Spain.

Mar Hernández-Guillamon (M)

Neurovascular Research Lab. Vall D'Hebron Research Institute, Universitat Autònoma de Barcelona, Edifici Mediterrània, Planta 1ª, Laboratori 123, Passeig Vall d'Hebron 119-129, 08035, Barcelona, CP, Spain.

Pilar Delgado (P)

Neurovascular Research Lab. Vall D'Hebron Research Institute, Universitat Autònoma de Barcelona, Edifici Mediterrània, Planta 1ª, Laboratori 123, Passeig Vall d'Hebron 119-129, 08035, Barcelona, CP, Spain. pilar.delgado@vhir.org.
Vall D'Hebron University Hospital, Universitat Autònoma de Barcelona, Dementia Unit, Neurology Service, Barcelona, Spain. pilar.delgado@vhir.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH